Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (23)
  • Open Access

    ARTICLE

    miR-30a-5p/PHTF2 axis regulates the tumorigenesis and metastasis of lung adenocarcinoma

    LIJUAN ZHANG1,#, QINGYIN MENG2,#, LI ZHUANG1, QUAN GONG1, XIANDA HUANG3, XUEQIN LI1, SHIJUAN LI1, GUOQIN WANG4, XICAI WANG5,*

    BIOCELL, Vol.48, No.4, pp. 581-590, 2024, DOI:10.32604/biocell.2024.047260

    Abstract Background: Lung adenocarcinoma is a very pervasive histological form of lung cancers, and inhibiting metastasis is crucial for effective treatment. In this investigation, we explored the functional interaction of miR-30a-5p and the putative transcription factor 2 of the homeodomain (PHTF2) in dictating the aggressiveness and metastasis of lung adenocarcinoma. Method: We collected clinical samples to evaluate the expression patterns of miR-30a-5p and PHTF2 in lung adenocarcinoma along with normal tissues. Cellular experiments including cell count kit (CCK)-8 growth assay, apoptosis analysis, migration and invasion examinations were performed to assess the aggressiveness of lung adenocarcinoma cells. Furthermore, we examined tumorigenesis and… More > Graphic Abstract

    miR-30a-5p/PHTF2 axis regulates the tumorigenesis and metastasis of lung adenocarcinoma

  • Open Access

    ARTICLE

    miR-125b reverses cisplatin resistance by regulating autophagy via targeting RORA/BNIP3L axis in lung adenocarcinoma

    LEI LIU1, NA GUO1, XIANGLING LI2, QIAN XU2, RUILONG HE3, LIMIN CHENG4, CHUNYAN DANG3, XINYU BAI3, YIYING BAI3, XIN WANG3, QIANHUI CHEN3, LI ZHANG3,*

    Oncology Research, Vol.32, No.4, pp. 643-658, 2024, DOI:10.32604/or.2023.044491

    Abstract The platinum-based chemotherapy is one of the most frequently used treatment protocols for lung adenocarcinoma (LUAD), and chemoresistance, however, usually results in treatment failure and limits its application in the clinic. It has been shown that microRNAs (miRNAs) play a significant role in tumor chemoresistance. In this study, miR-125b was identified as a specific cisplatin (DDP)-resistant gene in LUAD, as indicated by the bioinformatics analysis and the real-time quantitative PCR assay. The decreased serum level of miR-125b in LUAD patients was correlated with the poor treatment response rate and short survival time. MiR-125b decreased the A549/DDP proliferation, and the multiple… More >

  • Open Access

    ARTICLE

    Identification of prognostic molecular subtypes and model based on CD8+ T cells for lung adenocarcinoma

    HONGMIN CAO1,#,*, YING XUE2,#, FEI WANG1, GUANGYAO LI1, YULAN ZHEN1, JINGWEN GUO1

    BIOCELL, Vol.48, No.3, pp. 473-490, 2024, DOI:10.32604/biocell.2024.048946

    Abstract Background: Cytotoxic T lymphocytes (CD8+ T) cells function critically in mediating anti-tumor immune response in cancer patients. Characterizing the specific functions of CD8+ T cells in lung adenocarcinoma (LUAD) could help better understand local anti-tumor immune responses and estimate the effect of immunotherapy. Methods: Gens related to CD8+ T cells were identified by cluster analysis based on the single-cell sequencing data of three LUAD tissues and their paired normal tissues. Weighted gene co-expression network analysis (WGCNA), consensus clustering, differential expression analysis, least absolute shrinkage and selection operator (LASSO) and Cox regression analysis were conducted to classify molecular subtypes for LUAD… More > Graphic Abstract

    Identification of prognostic molecular subtypes and model based on CD8+ T cells for lung adenocarcinoma

  • Open Access

    ARTICLE

    MicroRNA (let-7b-5p)-targeted DARS2 regulates lung adenocarcinoma growth by PI3K/AKT signaling pathway

    YUANYUAN XU, XIAOKE CHEN*

    Oncology Research, Vol.32, No.3, pp. 517-528, 2024, DOI:10.32604/or.2023.030293

    Abstract Background: The aberrant intracellular expression of a mitochondrial aspartyl-tRNA synthetase 2 (DARS2) has been reported in human cancers. Nevertheless, its critical role and detailed mechanism in lung adenocarcinoma (LUAD) remain unexplored. Methods: Initially, The Cancer Genome Atlas (TCGA)-based Gene Expression Profiling Interactive Analysis (GEPIA) database () was used to analyze the prognostic relevance of DARS2 expression in LUAD. Further, cell counting kit (CCK)-8, immunostaining, and transwell invasion assays in LUAD cell lines in vitro, as well as DARS2 silence on LUAD by tumorigenicity experiments in vivo in nude mice, were performed. Besides, we analyzed the expression levels of p-PI3K (phosphorylated-Phosphotylinosital3… More >

  • Open Access

    ARTICLE

    Extensive prediction of drug response in mutation-subtype-specific LUAD with machine learning approach

    KEGANG JIA1,#, YAWEI WANG2,#, QI CAO3,*, YOUYU WANG1,*

    Oncology Research, Vol.32, No.2, pp. 409-419, 2024, DOI:10.32604/or.2023.042863

    Abstract Background: Lung cancer is the most prevalent cancer diagnosis and the leading cause of cancer death worldwide. Therapeutic failure in lung cancer (LUAD) is heavily influenced by drug resistance. This challenge stems from the diverse cell populations within the tumor, each having unique genetic, epigenetic, and phenotypic profiles. Such variations lead to varied therapeutic responses, thereby contributing to tumor relapse and disease progression. Methods: The Genomics of Drug Sensitivity in Cancer (GDSC) database was used in this investigation to obtain the mRNA expression dataset, genomic mutation profile, and drug sensitivity information of NSCLS. Machine Learning (ML) methods, including Random Forest… More >

  • Open Access

    ARTICLE

    Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay

    HONGYUAN LIANG1,#, YANQIU LI2,#, YONGGANG QU3, LINGYUN ZHANG4,*

    Oncology Research, Vol.32, No.2, pp. 393-407, 2024, DOI:10.32604/or.2023.031134

    Abstract Advanced LUAD shows limited response to treatment including immune therapy. With the development of sequencing omics, it is urgent to combine high-throughput multi-omics data to identify new immune checkpoint therapeutic response markers. Using GSE72094 (n = 386) and GSE31210 (n = 226) gene expression profile data in the GEO database, we identified genes associated with lung adenocarcinoma (LUAD) death using tools such as “edgeR” and “maftools” and visualized the characteristics of these genes using the “circlize” R package. We constructed a prognostic model based on death-related genes and optimized the model using LASSO-Cox regression methods. By calculating the cell death… More >

  • Open Access

    ARTICLE

    FGD5 as a novel prognostic biomarker and its association with immune infiltrates in lung adenocarcinoma

    ZHONGXIANG TANG1,2, LILI WANG1,2, GUOJUN WU1,2, LING QIN1,2,*, YURONG TAN1,2,*

    BIOCELL, Vol.47, No.11, pp. 2503-2516, 2023, DOI:10.32604/biocell.2023.031565

    Abstract Background: Non-small cell lung cancer (NSCLC) has a poor prognosis with a low 5-year survival rate. Lung adenocarcinoma (LUAD) accounts for 50%. Facio-genital dysplasia-5 (FGD5), a member of a subfamily of Rho GTP-GDP exchange factors, may be a good molecular biomarker for diagnosis and prognosis. Objective: To explore the clinical application of FGD5, the study was designed to investigate the prognosis value of FGD5 expression and its correlation with immune infiltrates in LUAD patients. Methods: Through the Wilcoxon signed-rank test and logistic regression, the correlation between clinical characteristics and FGD5 expression was analyzed. Kaplan–Meier plotter analysis, Cox regression, and a… More > Graphic Abstract

    FGD5 as a novel prognostic biomarker and its association with immune infiltrates in lung adenocarcinoma

  • Open Access

    ARTICLE

    Analysis of functional hub genes indicates DLGAP5 is linked to lung adenocarcinoma prognosis

    HAOSHENG ZHENG1,#, RUIJUN LIN2,#, WEIJIE CAI1, YUZHEN ZHENG1, XINGPING YANG1, ZUI LIU1, FEI QIN1, YONGJIE CAI3, XIANYU QIN1,*, HONGYING LIAO1,*

    BIOCELL, Vol.47, No.11, pp. 2453-2469, 2023, DOI:10.32604/biocell.2023.030032

    Abstract Introduction: The difficulty in treating lung adenocarcinoma (LUAD) is caused by a shortage of knowledge about the biological mechanisms and a lack of treatment choices. Objectives: The aim of this study was to identify a valuable molecular target for the treatment of LUAD. Methods: Using multiple databases, we screened for hub genes in LUAD using Cytoscape and explored the expression and prognosis of DLG associated protein 5 (DLGAP5) in LUAD. We investigated the genetic variation, functional enrichment, and epigenetic activity of DLGAP5. Furthermore, we evaluated the relationship between the tumor microenvironment (TME) and DLGAP5. Results: Our study identified 10 hub… More > Graphic Abstract

    Analysis of functional hub genes indicates DLGAP5 is linked to lung adenocarcinoma prognosis

  • Open Access

    ARTICLE

    Identification of lncRNAs associated with T cells as potential biomarkers and therapeutic targets in lung adenocarcinoma

    LU SUN1,2, HUAICHENG TAN1, TING YU3, RUICHAO LIANG4,*

    Oncology Research, Vol.31, No.6, pp. 967-988, 2023, DOI:10.32604/or.2023.042309

    Abstract Lung adenocarcinoma (LUAD) is the most common and deadliest subtype of lung cancer. To select more targeted and effective treatments for individuals, further advances in classifying LUAD are urgently needed. The number, type, and function of T cells in the tumor microenvironment (TME) determine the progression and treatment response of LUAD. Long noncoding RNAs (lncRNAs), may regulate T cell differentiation, development, and activation. Thus, our aim was to identify T cell-related lncRNAs (T cell-Lncs) in LUAD and to investigate whether T cell-Lncs could serve as potential stratifiers and therapeutic targets. Seven T cell-Lncs were identified to further establish the T… More >

  • Open Access

    ARTICLE

    Polo-like kinase 1 suppresses lung adenocarcinoma immunity through necroptosis

    PENGCHENG ZHANG1,#,*, XINGLONG ZHANG2,#, YONGFU ZHU3, YIYI CUI1, JING XU4, WEIPING ZHANG1,*

    Oncology Research, Vol.31, No.6, pp. 937-953, 2023, DOI:10.32604/or.2023.030933

    Abstract Polo-like kinase 1 (PLK1) plays a crucial role in cell mitosis and has been associated with necroptosis. However, the role of PLK1 and necroptosis in lung adenocarcinoma (LA) remains unclear. In this study, we analyzed The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression databases to evaluate the prognostic value and mechanistic role of PLK1 in LA. PLK1 was found to be highly expressed in LA and was positively associated with advanced disease staging and poor survival outcomes. Functional enrichment analysis showed that PLK1 was involved in cell mitosis, neurotransmitter transmission, and drug metabolism. Further analysis using single-sample gene set enrichment… More > Graphic Abstract

    Polo-like kinase 1 suppresses lung adenocarcinoma immunity through necroptosis

Displaying 1-10 on page 1 of 23. Per Page